Leading Across Borders: A Medical Device CEO’s Playbook - Show #148

This episode is for medical device companies expanding into global markets—covering regulatory approvals, CE marking, clinical evidence, labeling, IFUs, and localization. In this conversation, Wendy Mackenzie Pease sits down with Alain Tranchemontagne, CEO of Alleviate, who brings 30+ years of experience leading global medical device organizations—from startups to Fortune 50 companies. They unpack what it really takes to enter new markets, from navigating regulatory pathways and generating the right clinical evidence to building local teams that can execute effectively on the ground. For medical device companies, global expansion isn’t just about demand—it’s about meeting strict regulatory requirements, ensuring labeling and IFU accuracy, and avoiding costly delays tied to language and compliance missteps. This episode highlights how experienced leaders approach market entry with precision, speed, and a deep understanding of risk. What you’ll learn: How to approach global market entry in regulated environments: How to sequence markets, align with CE marking and other regulatory pathways, and prepare the clinical and technical documentation required for approval How to build effective international teams: Why local leadership, KOL engagement, and early performance measurement are critical when launching in new healthcare markets Why translation and localization are high-risk in medical devices: How errors in IFUs, labeling, and technical documentation can delay approvals, trigger compliance issues, or create patient safety risks—and why specialized expertise is essential About Rapport International: Rapport International supports medical device companies expanding globally with specialized translation and localization for IFUs, labeling, clinical documentation, and regulatory submissions. Our team understands the precision required in regulated environments—helping ensure terminology consistency, compliance with global standards, and accuracy that reduces approval delays and patient risk.